Aesculap Biologics, LLC Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of NOVOCART® 3D in Patients with Articular Cartilage Defects of the Knee

By In The News
February 28, 2019 in The Headlines

Recommended Posts

In The News

Posted February 28, 2019

- Share

Posted February 28, 2019

CENTER VALLEY, Pa., Feb. 28, 2019 /PRNewswire/ -- Aesculap Biologics, LLC ("Aesculap Biologics") announced today that it has successfully achieved 50 percent enrollment in the ongoing Phase 3 clinical trial of NOVOCART® 3D, an autologous chondrocyte transplantation system designed to...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  222047
2. Jaydee
  17801
3. deicer
  13355
4. Kip Powick
  12313
5. dagger
  9614
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  272.5k
- Total Posts
  
  565k

Sign In

Aesculap Biologics, LLC Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of NOVOCART® 3D in Patients with Articular Cartilage Defects of the Knee

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support